Cancer Treatment Reviews
Volume 30, Issue 7 , Pages 643-650 , November 2004

Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines

References 

  1. Weiss RB. The anthracyclines: will we ever find a better doxorubicin. Semin. Oncol. 1992;19:670–686
  2. Gianni L, Munzone E, Capri G, et al.  Paclitaxel by 3-h infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol. 1995;13:2688–2699
  3. Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin. Oncol. 1996;23:23–27
  4. Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 1999;17:3828–3834
  5. Hensley ML, Schuchter LM, Lindley C, et al.  American Society of clinical oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 1999;17:3333–3355
  6. Hellmann K. Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy products: a critique. J. Clin. Oncol. 2000;18:2004–2006
  7. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 1991;324:808–815
  8. Von Hoff DD, Layard MW, Basa P, et al.  Risk factors for doxorubicin induced congestive heart failure. Ann. Intern. Med. 1979;91:710–717
  9. Speyer JL, Green MD, Zeleniuch-Jacotte A, et al.  ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 1992;10:117–127
  10. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672–1677
  11. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin. Oncol. 1992;19:529–542
  12. Lipshultz SE, Lipsitz SR, Mone SM, et al.  Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. 1995;332:1738–1743
  13. Legha SS, Benjamin RS, Mackay B, et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 1982;96:133–139
  14. Shapira J, Gottfried M, Lisner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-h infusion regimen. Cancer. 1990;65:870–873
  15. Casper ES, Gaynor JJ, Hadju SI, et al.  A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer. 1991;68:1221–1229
  16. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure function relationships in doxorubicin cardiomyopathy. Am. Heart J. 1981;102:709–718
  17. Lipshultz SE, Sallan SE, Giantris AL, Lipsitz SR, Dalton V, Colan SD. 48 h continuous doxorubicin infusion is not cardioprotective in children assessed 18 months later: the DFCI 91001 ALL protocol. Proc. Am. Soc. Clin. Oncol. 1998;17:2028; (abstr)
  18. Dieras V, Barthier S, Beuzeboc P, et al.  A phase II study of Taxotere (T) in combination with doxorubicin (A) as first line chemotherapy (CT) of metastatic breast cancer (MBC). Breast Cancer Res. Treat. 1998;50:226; (abstr)
  19. Johnston SR, Gore ME. Caelyx: phase II studies in ovarian cancer. Eur. J. Cancer. 2001;37(Suppl. 9):S8, .S14
  20. Slamon DJ, Leyland-Jones B, Shak S, et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001;344:783–792
  21. Perez EA, Hortobagyi GN. Ongoing and planned adjuvant trials with trastuzumab. Semin. Oncol. 2000;27:26–32
  22. Goram AL, Richmond PL. Pegylated liposomal doxorubicin: tolerability and toxicity. Pharmacotherapy. 2001;21:751–763
  23. Nabholtz JM, Mackey JR, Smylie M, et al.  Final results of a Phase II study of Taxotere (T), doxorubicin (A) and cyclophosphamide (C) (TAC) as first line chemotherapy (CT) in metastatic breast cancer (MBC) patients. Breast Cancer Res. Treat. 1998;50:227; (abstr)
  24. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. Cancer Res Clin Oncol 2003;129: [in press; will be published November 2003, issue 12; page numbers to be confirmed]
  25. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am. J. Med. 1978;65:823–832
  26. Herman EH, Witiak DT, Hellmann K, Waravdekar VS. Biological properties of ICRF-159 and related bis (dioxopiperazine) compounds. Adv. Pharmacol. Chemother. 1982;19:249–290
  27. Herman EH, Ardalan B, Bier C, Waravdekar VS, Krop S. Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treat Rep. 1979;63:89–92
  28. Herman EH, Ferrans VJ, Myers CE, Van Vleet JF. Comparison of the effectiveness of (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res. 1985;45:276–281
  29. Herman EH, Ferrans VJ, Jordan W, Ardalan B. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res. Commun. Chem. Pathol. Pharmacol. 1981;31:85–97
  30. Herman EH, Ferrans VJ. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187). Cancer Res. 1981;41:3436–3440
  31. Herman EH, Ferrans VJ. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab. Invest. 1983;49:69–77
  32. Herman EH, Ferrans VJ. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother. Pharmacol. 1986;16:102–106
  33. Dardir M, Herman EH, Ferrans VJ. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats. Cancer Chemother. Pharmacol. 1989;23:269–275
  34. Herman EH, Ferrans VJ, Young RSK, Hamlin RL. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res. 1988;48:6918–6925
  35. Herman EH, El-Hage AN, Ferrans VJ, Witiak DT. Reduction by ICRF-187 of acute doxorubicin toxicity in Syrian golden hamsters. Res. Commun. Chem. Pathol. Pharmacol. 1983;40:217–231
  36. Ten Bokkel Huinink WW, Schreuder JE, Dubbelman R, et al.  ICRF 187 protects against doxorubicin induced cardiomyopathy. Ann. Oncol. 1992;3:114; (abstr)
  37. Feldmann JE, Jones SE, Weisberg SR, et al.  Advanced small cell lung cancer treated with CAV (cyclophosphamide+Adriamycin®+vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR529, ICRF187, Zinecard®). Proc. Am. Soc. Clin. Oncol. 1992;11:993; (abstr)
  38. Lopez M, Vici P, Di Lauro L, et al.  Randomized prospective clinical trial to evaluate cardio-protection of dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J. Clin. Oncol. 1998;16:1–7
  39. Swain SM, Whaley FS, Gerber MC, et al.  Cardioprotective with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 1997;15:1318–1322
  40. Speyer JL, Green MD, Kramer E, et al.  Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. New Engl. J. Med. 1988;319:745–752
  41. Swain SM, Whaley FS, Gerber MC, et al.  Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. 1997;15:1333–1340
  42. Venturini M, Michelotti A, Del Mastro L, et al.  Multicenter randomized controlled clinical trial to evaluate cardio-protection of dexrazoxane versus no cardio-protection in women receiving epirubicin chemotherapy for advanced breast cancer. J. Clin. Oncol. 1996;14:3112–3120
  43. Wexler LH, Andrich MP, Venzon D, et al.  Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. 1996;14:362–372
  44. Rubio ME, Wiegman A, Naeff MSJ, et al.  ICRF 187 (Cardioxane) protection against doxorubicin induced cardiomyopathy in paediatric osteosarcoma patients. Proc. Am. Soc. Clin. Oncol. 1995;14:440; (abstr)
  45. Bu'Lock FA, Gabriel HM, Oakhill A, Mott MG, Martin RP. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br. Heart J. 1993;70:185–188
  46. Schiavetti A, Castello MA, Versacci P, et al.  Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Pediatr. Hematol. Oncol. 1997;14:213–222
  47. Chiron Therapeutics, Amsterdam, The Netherlands. A phase III randomised comparison of cardioprotection with Cardioxane (dexrazoxane, ICRF187) versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. Clinical study report EC-CX-006, 1999
  48. Wadler S, Green MD, Muggia FM. Synergistic activity of doxorubicin and the bisdioxopiperazine (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) against murine sarcoma S180 cell line. Cancer Res. 1986;46:1176–1181
  49. Soudon J. Study of the in vitro cytotoxicity of doxorubicin combined with Cardioxane® to 9 breast cancer cell lines. French Marketing Authorization Application File
  50. Verhoef V, Bell V, Filppi J. Effect of the cardioprotective agent ADR-529 (ICRF187) on the antitumor activity of doxorubicin. Proc. Am. Assoc. Cancer Res. 1988;29:

PII: S0305-7372(04)00102-1

doi: 10.1016/j.ctrv.2004.06.002

Cancer Treatment Reviews
Volume 30, Issue 7 , Pages 643-650 , November 2004

Article Tools

* Image Usage & Resolution